Products from BPS Bioscience require a minimum order value above 400€
Applications: Expression of human DLL3 in cells of interest.Generate cell pools or stable cell lines expressing human DLL3 following puromycin selection
Background: DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine).
Description: DLL3 (Delta-like protein 3) Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These particles contain human DLL3 (NM_016941.3) driven by a CMV promoter and a puromycin selection marker.
Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
References: Chapman G, et al., 2011 Hum Mol Genet. 20(5):905-16Ladi E, et al., 2005 J Cell Biol. 170 (6): 983-992Kunnimalaiyaan M, et al., 2007 The oncologist. 12(5):535-42Owen D, et al., 2019 J Hematol Oncol. 12(1): 61
English
Deutsch
